ADC Therapeutics SA ADCT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ADCT is a good fit for your portfolio.
News
-
ADC Therapeutics Announces Updates on LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in Combination with Glofitamab or Mosunetuzumab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
-
ADC Therapeutics to Host a Virtual Research Investor Event on Tuesday, April 9, 2024
-
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
-
ADC Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates
-
ADC Therapeutics to Participate in the Guggenheim 5th Annual Healthy Altitudes Summit
-
ADC Therapeutics to Host Fourth Quarter and Year-End 2023 Financial Results Conference Call on March 13, 2024
-
ADC Therapeutics Announces Abstracts Accepted for Presentation at the American Association for Cancer Research (AACR) Annual Meeting
-
ADC Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference
Trading Information
- Previous Close Price
- $4.97
- Day Range
- $4.71–5.00
- 52-Week Range
- $0.36–6.04
- Bid/Ask
- $3.99 / $5.50
- Market Cap
- $394.49 Mil
- Volume/Avg
- 276,687 / 672,725
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 5.62
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's product candidate includes ZYNLONTA, camidanlumab tesirine, ADCT-602, ADCT-601, ADCT-901, ADCT-701 and ADCT-212.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 274
- Website
- https://www.adctherapeutics.com
Comparables
Valuation
|
Metric
|
ADCT
|
MLTX
|
ACIU
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | — | 5.18 | 1.23 |
Price/Sales | 5.62 | — | 12.19 |
Price/Cash Flow | — | — | — |
Price/Earnings
ADCT
MLTX
ACIU
Financial Strength
|
Metric
|
ADCT
|
MLTX
|
ACIU
|
|---|---|---|---|
Quick Ratio | 4.49 | 51.38 | 8.74 |
Current Ratio | 4.97 | 51.59 | 9.22 |
Interest Coverage | −3.45 | — | −313.02 |
Quick Ratio
ADCT
MLTX
ACIU
Profitability
|
Metric
|
ADCT
|
MLTX
|
ACIU
|
|---|---|---|---|
Return on Assets (Normalized) | −49.55% | −11.20% | −30.01% |
Return on Equity (Normalized) | — | −12.51% | −33.60% |
Return on Invested Capital (Normalized) | −187.22% | −11.49% | −33.51% |
Return on Assets
ADCT
MLTX
ACIU
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Rnmjfndwnr | Bcrxz | $562.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Pjqrkxt | Pcvzjd | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Fmhywmxj | Vnqvbf | $99.5 Bil | |
MRNA
| Moderna Inc | Ywxbtkvqs | Yxcw | $38.8 Bil | |
ARGX
| argenx SE ADR | Vrdncqp | Kvwt | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Gqcgxdzp | Xhh | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Zbnbjrs | Cqdcny | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Bcwttzw | Smlvggf | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Mjktfknx | Xntkrhm | $12.5 Bil | |
INCY
| Incyte Corp | Ccpnnkhtw | Qtydt | $11.6 Bil |